Antipsychotic-like	antipsychotic-like	O	O
profile	profile	O	O
of	of	O	O
thioperamide	thioperamide	O	O
,	,	O	O
a	a	O	O
selective	selective	O	O
H3-receptor	h3-receptor	O	O
antagonist	antagonist	O	O
in	in	O	O
mice	mice	O	O
.	.	O	O

Experimental	experimental	O	O
and	and	O	O
clinical	clinical	O	O
evidence	evidence	O	O
points	points	O	O
to	to	O	O
a	a	O	O
role	role	O	O
of	of	O	O
central	central	O	O
histaminergic	histaminergic	O	O
system	system	O	O
in	in	O	O
the	the	O	O
pathogenesis	pathogenesis	O	O
of	of	O	O
schizophrenia	schizophrenia	O	S_disease
.	.	O	O

The	the	O	O
present	present	O	O
study	study	O	O
was	was	O	O
designed	designed	O	O
to	to	O	O
study	study	O	O
the	the	O	O
effect	effect	O	O
of	of	O	O
histamine	histamine	S_chemical	O
H(3)-receptor	h(3)-receptor	O	O
ligands	ligands	O	O
on	on	O	O
neuroleptic-induced	neuroleptic-induced	O	O
catalepsy	catalepsy	O	S_disease
,	,	O	O
apomorphine-induced	apomorphine-induced	O	O
climbing	climbing	O	O
behavior	behavior	O	O
and	and	O	O
amphetamine-induced	amphetamine-induced	O	O
locomotor	locomotor	O	O
activities	activities	O	O
in	in	O	O
mice	mice	O	O
.	.	O	O

Catalepsy	catalepsy	O	S_disease
was	was	O	O
induced	induced	O	O
by	by	O	O
haloperidol	haloperidol	S_chemical	O
(	(	O	O
2	2	O	O
mg/kg	mg/kg	O	O
p.o	p.o	O	O
.	.	O	O
)	)	O	O
,	,	O	O
while	while	O	O
apomorphine	apomorphine	S_chemical	O
(	(	O	O
1.5	1.5	O	O
mg/kg	mg/kg	O	O
s.c	s.c	O	O
.	.	O	O
)	)	O	O
and	and	O	O
amphetamine	amphetamine	S_chemical	O
(	(	O	O
2	2	O	O
mg/kg	mg/kg	O	O
s.c	s.c	O	O
.	.	O	O
)	)	O	O
were	were	O	O
used	used	O	O
for	for	O	O
studying	studying	O	O
climbing	climbing	O	O
behavior	behavior	O	O
and	and	O	O
locomotor	locomotor	O	O
activities	activities	O	O
,	,	O	O
respectively	respectively	O	O
.	.	O	O

(R)-alpha-methylhistamine	(r)-alpha-methylhistamine	O	O
(	(	O	O
RAMH	ramh	S_chemical	O
)	)	O	O
(	(	O	O
5	5	O	O
microg	microg	O	O
i.c.v	i.c.v	O	O
.	.	O	O
)	)	O	O
and	and	O	O
thioperamide	thioperamide	O	O
(	(	O	O
THP	thp	S_chemical	O
)	)	O	O
(	(	O	O
15	15	O	O
mg/kg	mg/kg	O	O
i.p	i.p	O	O
.	.	O	O
)	)	O	O
,	,	O	O
per	per	O	O
se	se	O	S_disease
did	did	O	O
not	not	O	O
cause	cause	O	O
catalepsy	catalepsy	O	S_disease
.	.	O	O

Administration	administration	O	O
of	of	O	O
THP	thp	S_chemical	O
(	(	O	O
3.75	3.75	O	O
,	,	O	O
7.5	7.5	O	O
and	and	O	O
15	15	O	O
mg/kg	mg/kg	O	O
i.p	i.p	O	O
.	.	O	O
)	)	O	O
1	1	O	O
h	h	S_chemical	O
prior	prior	O	O
to	to	O	O
haloperidol	haloperidol	S_chemical	O
resulted	resulted	O	O
in	in	O	O
a	a	O	O
dose-dependent	dose-dependent	O	O
increase	increase	O	O
in	in	O	O
the	the	O	O
catalepsy	catalepsy	O	S_disease
times	times	O	O
(	(	O	O
P	p	O	O
<	<	O	O
0.05	0.05	O	O
)	)	O	O
.	.	O	O

However	however	O	O
,	,	O	O
pretreatment	pretreatment	O	O
with	with	O	O
RAMH	ramh	S_chemical	O
significantly	significantly	O	O
reversed	reversed	O	O
such	such	O	O
an	an	O	O
effect	effect	O	O
of	of	O	O
THP	thp	S_chemical	O
(	(	O	O
15	15	O	O
mg/kg	mg/kg	O	O
i.p	i.p	O	O
.	.	O	O
)	)	O	O
.	.	O	O

RAMH	ramh	S_chemical	O
per	per	O	O
se	se	O	S_disease
showed	showed	O	O
significant	significant	O	O
reduction	reduction	O	O
in	in	O	O
locomotor	locomotor	O	O
time	time	O	O
,	,	O	O
distance	distance	O	O
traveled	traveled	O	O
and	and	O	O
average	average	O	O
speed	speed	O	O
but	but	O	O
THP	thp	S_chemical	O
(	(	O	O
15	15	O	O
mg/kg	mg/kg	O	O
i.p	i.p	O	O
.	.	O	O
)	)	O	O
per	per	O	O
se	se	O	S_disease
had	had	O	O
no	no	O	O
effect	effect	O	O
on	on	O	O
these	these	O	O
parameters	parameters	O	O
.	.	O	O

On	on	O	O
amphetamine-induced	amphetamine-induced	O	O
hyperactivity	hyperactivity	O	S_disease
,	,	O	O
THP	thp	S_chemical	O
(	(	O	O
3.75	3.75	O	O
and	and	O	O
7.5	7.5	O	O
mg/kg	mg/kg	O	O
i.p	i.p	O	O
.	.	O	O
)	)	O	O
reduced	reduced	O	O
locomotor	locomotor	O	O
time	time	O	O
,	,	O	O
distance	distance	O	O
traveled	traveled	O	O
and	and	O	O
average	average	O	O
speed	speed	O	O
(	(	O	O
P	p	O	O
<	<	O	O
0.05	0.05	O	O
)	)	O	O
.	.	O	O

Pretreatment	pretreatment	O	O
with	with	O	O
RAMH	ramh	S_chemical	O
(	(	O	O
5	5	O	O
microg	microg	O	O
i.c.v	i.c.v	O	O
.	.	O	O
)	)	O	O
could	could	O	O
partially	partially	O	O
reverse	reverse	O	O
such	such	O	O
effects	effects	O	O
of	of	O	O
THP	thp	S_chemical	O
(	(	O	O
3.75	3.75	O	O
mg/kg	mg/kg	O	O
i.p	i.p	O	O
.	.	O	O
)	)	O	O
.	.	O	O

Climbing	climbing	O	O
behavior	behavior	O	O
induced	induced	O	O
by	by	O	O
apomorphine	apomorphine	S_chemical	O
was	was	O	O
reduced	reduced	O	O
in	in	O	O
animals	animals	O	O
treated	treated	O	O
with	with	O	O
THP	thp	S_chemical	O
.	.	O	O

Such	such	O	O
an	an	O	O
effect	effect	O	O
was	was	O	O
,	,	O	O
however	however	O	O
,	,	O	O
reversed	reversed	O	O
in	in	O	O
presence	presence	O	O
of	of	O	O
RAMH	ramh	S_chemical	O
.	.	O	O

THP	thp	S_chemical	O
exhibited	exhibited	O	O
an	an	O	O
antipsychotic-like	antipsychotic-like	O	O
profile	profile	O	O
by	by	O	O
potentiating	potentiating	O	O
haloperidol-induced	haloperidol-induced	O	O
catalepsy	catalepsy	O	S_disease
,	,	O	O
reducing	reducing	O	O
amphetamine-induced	amphetamine-induced	O	O
hyperactivity	hyperactivity	O	S_disease
and	and	O	O
reducing	reducing	O	O
apomorphine-induced	apomorphine-induced	O	O
climbing	climbing	O	O
in	in	O	O
mice	mice	O	O
.	.	O	O

Such	such	O	O
effects	effects	O	O
of	of	O	O
THP	thp	S_chemical	O
were	were	O	O
reversed	reversed	O	O
by	by	O	O
RAMH	ramh	S_chemical	O
indicating	indicating	O	O
the	the	O	O
involvement	involvement	O	O
of	of	O	O
histamine	histamine	S_chemical	O
H(3)-receptors	h(3)-receptors	O	O
.	.	O	O

Findings	findings	O	O
suggest	suggest	O	O
a	a	O	O
potential	potential	O	O
for	for	O	O
H(3)-receptor	h(3)-receptor	O	O
antagonists	antagonists	O	O
in	in	O	O
improving	improving	O	O
the	the	O	O
refractory	refractory	O	O
cases	cases	O	O
of	of	O	O
schizophrenia	schizophrenia	O	S_disease
.	.	O	O

